JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB99816

Anti-Human IgG4 pFc’ [HP6023] (Alkaline Phosphatase)

Anti-Human IgG4 pFc’ [HP6023] (Alkaline Phosphatase)

Be the first to review this product! Submit a review

|

(1 Publication)

Suitable for Dot, WB, ICC, IHC-Fr, ELISA. Cited in 1 publication.

查看别名

Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4

不同偶联物与剂型 (4)

  • Unconjugated

    Anti-Human IgG4 pFc’ [HP6023]

  • 519 FITC

    Anti-Human IgG4 pFc’ [HP6023] (FITC)

  • Biotin

    Anti-Human IgG4 pFc’ [HP6023] (Biotin)

  • 578 PE

    Anti-Human IgG4 pFc’ [HP6023] (PE)

关键信息

宿主种属

Mouse

靶标种属

Human

靶标亚型

IgG4

靶标特异性

Fc region

最低交叉反应
预吸附

No

偶联物

Alkaline Phosphatase

激发波长/发射波长
应用

IHC-Fr, WB, Dot, ICC, ELISA

applications

克隆

Monoclonal

克隆号

HP6023

亚型

IgG3

轻链类型

kappa

免疫原

Full Length Protein corresponding to Human IGHG4. The exact immunogen used to generate this antibody is proprietary information.

P01861

特异性

ab99816 reacts with the pFc’ portion of the heavy chain of Human IgG4.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Dot": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>for Dot and slot immunoblotting</p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ICC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "IHC-Fr": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/500 - 1/1000", "notes":"<p></p>" } } }

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 8 Preservative: 0.1% Sodium azide Constituents: 50% Glycerol (glycerin, glycerine), 0.605% Tris, 0.0095% Magnesium chloride
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

产品实验方案

靶点信息

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region interacts (via the fragment crystallizable, Fc) with the Fc receptors on innate immune cells to mediate humoral effector functions. Ig gamma-4 (IgG4) isotype does not elicit antibody-dependent cellular cytotoxicity (ADDC) or complement-dependent cytotoxicity (CDC). Instead it is likely involved in immune tolerance mechanisms to allergens and parasites either by blocking IgE-antigen complex formation or by directly inhibiting mast cell degranulation through Fc receptor signaling. In the context of tumorigenesis, it may participate in immunosuppressive mechanisms.
See full target information IGHG4

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of neurology 271:2736-2744 PubMed38386048

2024

Different pain phenotypes are associated with anti-Caspr2 autoantibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Patrik Greguletz,Maria Plötz,Carolin Baade-Büttner,Christian G Bien,Katharina Eisenhut,Christian Geis,Robert Handreka,Jaqueline Klausewitz,Peter Körtvelyessy,Stjepana Kovac,Andrea Kraft,Jan Lewerenz,Michael Malter,Michael Nagel,Felix von Podewils,Harald Prüß,Anna Rada,Johanna Rau,Sebastian Rauer,Rosa Rößling,Thomas Seifert-Held,Kai Siebenbrodt,Kurt-Wolfram Sühs,Simone C Tauber,Franziska Thaler,Judith Wagner,Jonathan Wickel,Frank Leypoldt,Heike L Rittner,Claudia Sommer,Carmen Villmann,Kathrin Doppler
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com